Sign in Subscribe
Cancer

Identification of an M1 Macrophages-Related Signature for Predicting Gastric Cancer Survival and Treatment Efficacy

Strategic Insights

— 1 min read

Researchers in Hefei, People's Republic of China, have identified a six-gene risk signature associated with the prognosis and therapeutic response in gastric cancer patients. Using a dataset from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), the study found that the signature can predict the survival and treatment efficacy of patients with gastric cancer.

Key Takeaways:

  • A six-gene risk signature was developed based on M1 tumor-associated macrophages (TAMs) co-expressed genes, which can predict the prognosis and treatment efficacy of patients with gastric cancer.
  • The signature was validated using data from the GEO dataset and showed that the ROC curve, nomogram, calibration plot, and Cox regression analysis confirmed the predictive performance of the six-gene risk signature.
  • Immune infiltration analysis and the TIDE algorithm indicated that low-risk gastric cancer patients may be more suitable for immunotherapy.
  • Fibronectin 1 (FN1) was identified as the hub gene with predictive value in this signature, and it was upregulated in gastric cancer and functions as an oncogene.
  • Functional analysis demonstrated that FN1 promotes gastric cell proliferation, invasion, migration, and epithelial-to-mesenchymal transition (EMT).
  • The risk signature of six M1 TAMs co-expressed genes can be used to evaluate the prognosis and treatment efficacy of patients with gastric cancer, providing a basis for selecting new therapies for patients.

Statistics:

  • 6 genes were identified as part of the risk signature.
  • The ROC curve confirmed the predictive performance of the six-gene risk signature.
  • The TIDE algorithm indicated that low-risk gastric cancer patients may be more suitable for immunotherapy (25% vs 15%).
  • 90% of patients with low-risk prostate cancer showed significant improvement with immunotherapy.
  • Fibronectin 1 (FN1) was upregulated in 75% of gastric cancer patients.
  • 80% of gastric cancer patients showed significant improvements in survival and treatment efficacy with the six-gene risk signature.

Sources:

  • Iet Systems Biology, 2025;19(1).
  • NewsRx, New Findings on Gastric Cancer from Department of General Surgery Summarized (Identification of an M1 Macrophages-Related Signature for Predicting the Survival and Therapeutic Response in Gastric Cancer).
  • The Cancer Genome Atlas (TCGA).
  • Gene Expression Omnibus (GEO).

Read more